Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Long QT Syndrome Companies

Specializing in cardiac health, Long QT Syndrome companies focus on developing diagnostics and treatments for this genetic heart rhythm disorder. These companies contribute to advancements in managing Long QT Syndrome for improved patient care.

long QT syndrome market

Latest Long QT Syndrome Companies Updates

January 2024: Actelion Pharmaceuticals (a Janssen company) announced the initiation of a Phase 3 clinical trial assessing the efficacy and safety of their potassium sodium adenosine triphosphatase (Na/K-ATPase) inhibitor verapamil in preventing syncope (fainting) episodes in LQTS patients.

November 2023: The US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Cohero BioScience's CBP-501 for reducing mortality and morbidity in infants with LQTS. This designation expedites the development and review process for the drug.

August 2023: Biotronik received CE Mark approval for their Lumax HF7 ICD (implantable cardioverter defibrillator) designed specifically for pediatric patients with LQTS. This approval provides a smaller, more comfortable device option for younger LQTS patients.

December 2023: Invitae, a genetic testing company, partnered with the LQTS Foundation to expand access to genetic testing for LQTS. This partnership aims to improve early diagnosis and management of the condition.

October 2023: The Mayo Clinic and Pfizer entered into a strategic collaboration to develop and commercialize personalized medicine solutions for LQTS. This collaboration leverages Mayo Clinic's expertise in clinical care and research with Pfizer's drug development capabilities.

List of Long QT Syndrome Key companies in the market:

Invitae Corporation (U.S.)

GeneDx. (U.S.)

Asper Biogene (Estonia)

Boston Scientific Corporation (U.S.)

Laboratory Corporation of America Holdings (U.S.)

Pfizer Inc. (U.S.)

Zydus Pharmaceuticals, Inc. (U.S.)

Aralez Pharmaceuticals Inc. (Canada)

AstraZeneca (U.K)

Torrent Pharmaceuticals Limited (India)

Lupin Pharmaceuticals, Inc. (U.S.)

Cipla Inc. (India)

Long QT Syndrome Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.